# Adaptive Biotechnologies Corporation (ADPT)

> Source: Nexqual · https://nexqual.com/ADPT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Adaptive Biotechnologies Corporation (ADPT), nexqual.com/ADPT" · informational, not investment advice.

**Price:** USD 25.58 (-0.16% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 25.62 · day 24.92–25.91 · 52w 12–30.74 · market cap $4.08B · NMS

## Key facts
- 2 of 80 tracked superinvestors hold ADPT (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 29.81 (range 21–35).
- Total return with dividends: 1Y +48.1% vs S&P 500 +18.1%; 5Y -23.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.1, revenue estimate $71.6M.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold ADPT. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 1.83% | $643M | Unchanged |
| Polen Capital | Polen Capital Management | 0.02% | $2.2M | Reduced -11.7% |

## Analysts
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 29.81 (low 21, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $28 → $32 |
| 2026-10-13 | Morgan Stanley | Target raised | Equal-Weight | $22 → $27 |
| 2026-10-01 | Guggenheim | Target raised | Buy | $25 → $32 |
| 2026-09-29 | Goldman Sachs | Initiated | Buy | $35 |
| 2026-09-22 | BTIG | Target raised | Buy | $25 → $34 |
| 2026-08-04 | Piper Sandler | Target raised | Overweight | $20 → $27.5 |
| 2026-07-30 | Morgan Stanley | Target raised | Equal-Weight | $20 → $22 |
| 2026-07-30 | TD Cowen | Target raised | Buy | $25 → $28 |
| 2026-07-30 | Guggenheim | Target raised | Buy | $22 → $25 |
| 2026-07-30 | BTIG | Target raised | Buy | $24 → $25 |
| 2026-07-09 | Morgan Stanley | Target raised | Equal-Weight | $18 → $20 |
| 2026-06-29 | Guggenheim | Target raised | Buy | $21 → $22 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +48.1% | -23.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +48.3% | -5.2% |
| Volatility (annualized) | 67.1% | 72.7% |
| Max drawdown | -39.4% (Nov 2025→Mar 2026) | -93.5% (Nov 2021→Apr 2024) |

## Peers (Diagnostics & Research)
VCYT (Veracyte, Inc.) USD 44.39 +2.97% · CDNA (CareDx, Inc.) USD 66.68 +1.90% · BLLN (BillionToOne, Inc.) USD 102.73 +8.78% · SHC (Sotera Health Company) USD 18.07 -0.77% · RDNT (RadNet, Inc.) USD 70.41 -1.54% · GRAL (GRAIL, Inc.) USD 135.46 -3.48%

## More
Full page: https://nexqual.com/ADPT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt